CDT Equity signs deal with Manoira to evaluate compounds for animal health products
CDT•CDT Equity entered an agreement for Manoira to evaluate AZD1656, certain cocrystal derivatives and AZD5904 for animal health products planned for launch in the first quarter of 2027. A successful evaluation could lead to licensing and commercialization discussions.
1. Compound evaluation
Manoira will assess CDT Equity’s clinical-stage assets, including AZD1656 and certain cocrystal derivatives, as well as AZD5904, for use in animal health products planned for launch in the first quarter of 2027. If the evaluation is successful, the companies would discuss licensing and commercialization for sales of the resulting products after launch.
